Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Source: View publication →
In this randomized, double-blind, placebo-controlled trial, once-weekly subcutaneous semaglutide was shown to be noninferior to placebo and superior in reducing the composite risk of major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
Key Findings
Study Design
Study Limitations
Clinical Significance
SUSTAIN-6 demonstrated that once-weekly semaglutide provides cardiovascular benefits in addition to its established glycemic-lowering and weight-loss effects in high-risk patients with type 2 diabetes, supporting its role as a therapeutic option for reducing cardiovascular risk in this population, despite the noted signal for increased retinopathy.
Historical Context
Following FDA mandates for all new antidiabetic medications to demonstrate cardiovascular safety, SUSTAIN-6 was conducted as a pre-approval cardiovascular outcomes trial (CVOT). It was one of the first major trials to evaluate the long-acting GLP-1 receptor agonist semaglutide, building upon the findings of previous trials like LEADER (liraglutide), which also established cardiovascular benefits for the GLP-1 receptor agonist class.
Guided Discussion
High-yield insights from every perspective
What are the structural modifications made to the semaglutide molecule compared to human GLP-1, and how do these changes influence its pharmacokinetic profile?
Key Response
Semaglutide is modified by substituting alanine with alpha-aminoisobutyric acid at position 8 to protect against Dipeptidyl Peptidase-4 (DPP-4) degradation and by attaching a C18 fatty diacid chain to lysine at position 26 via a spacer. These modifications facilitate strong albumin binding and reduce renal clearance, extending the half-life to approximately 7 days, which allows for once-weekly subcutaneous dosing compared to the minutes-long half-life of endogenous GLP-1.
While SUSTAIN-6 demonstrated cardiovascular benefits, what specific microvascular safety concern emerged, and how should this affect clinical monitoring for patients initiated on semaglutide?
Key Response
The trial found a statistically significant increase in diabetic retinopathy complications (HR 1.76) in the semaglutide group. This is thought to be related to the 'early worsening' phenomenon associated with rapid improvements in glycemic control in patients with pre-existing advanced retinopathy. Clinicians should ensure patients have a baseline eye exam and monitor for retinopathy progression, particularly in those with long-standing, poorly controlled diabetes and established eye disease.
The primary outcome in SUSTAIN-6 was a composite of MACE (CV death, nonfatal MI, or nonfatal stroke). How did the specific drivers of this outcome differ from those seen in the LEADER trial (liraglutide)?
Key Response
In SUSTAIN-6, the 26% reduction in MACE was primarily driven by a significant reduction in nonfatal stroke (HR 0.61) and a non-significant trend in nonfatal MI, but no reduction in CV death. In contrast, the LEADER trial showed a 13% reduction in MACE that was primarily driven by a significant reduction in cardiovascular mortality. This suggests that while GLP-1 RAs as a class provide CV protection, the individual components of that protection may vary by specific agent or trial population.
SUSTAIN-6 was powered as a non-inferiority trial to satisfy FDA safety requirements. Given the relatively small sample size (N=3,297) and short duration (2 years) compared to other CVOTs, how should we interpret the finding of 'superiority' for MACE?
Key Response
While the p-value for superiority was 0.02, the trial's primary intent was safety. The rapid divergence of the Kaplan-Meier curves suggests a potent effect on atherosclerotic events rather than heart failure. However, the small number of events (only 254 primary outcomes) means the point estimate for benefit is less precise than larger trials like REWIND or EXSCEL. It serves as a proof-of-concept for the high potency of semaglutide, but clinicians should recognize it was not designed to be a definitive superiority trial.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of the 1.8 non-inferiority margin for the upper boundary of the 95% confidence interval in SUSTAIN-6. What are the methodological implications of this threshold versus the more contemporary 1.3 margin?
Key Response
The 1.8 margin was established by the 2008 FDA Guidance for Industry to rule out 'excessive' CV risk in pre-approval or early post-approval stages. Because SUSTAIN-6 was a pre-approval trial for the once-weekly formulation, it used the more permissive 1.8 margin. Using a 1.3 margin would have required a much larger sample size to achieve sufficient power. The 1.8 margin allows for faster signal detection of harm but increases the risk of a Type I error regarding non-inferiority if the drug is marginally harmful but within the wide confidence interval.
If you were reviewing the SUSTAIN-6 manuscript, how would you address the discrepancy between the significant reduction in MACE and the lack of benefit in CV death, particularly in the context of the retinopathy findings?
Key Response
An editor would flag the potential for 'selective reporting' or 'multiplicity' concerns. With only 108 CV deaths in the entire study, the trial was severely underpowered for mortality. The editor would require the authors to emphasize that the MACE reduction was driven by nonfatal events (stroke). Furthermore, the editor would demand a rigorous analysis of the retinopathy data to determine if the effect was a direct drug toxicity or a metabolic consequence of rapid HbA1c reduction (the 'glucose-lowering paradox').
How did SUSTAIN-6 influence the evolution of the ADA Standards of Care regarding the hierarchy of GLP-1 RAs for patients with established ASCVD?
Key Response
SUSTAIN-6 provided the first evidence for the CV benefit of once-weekly semaglutide. Along with LEADER and PIONEER 6, it led the ADA to recommend GLP-1 RAs with 'proven CVD benefit' as a preferred second-line agent after metformin (or even first-line in some updates) for patients with established ASCVD. Current guidelines (e.g., ADA 2024) specifically list semaglutide as having a Grade A recommendation for reducing MACE, effectively moving it from a glucose-lowering choice to a primary cardioprotective strategy.
Clinical Landscape
Noteworthy Related Trials
EMPA-REG OUTCOME Trial
Tested
Empagliflozin 10/25mg daily
Population
T2DM patients with established CVD
Comparator
Placebo
Endpoint
3-point MACE
LEADER Trial
Tested
Liraglutide 1.8mg daily
Population
T2DM patients with high CV risk
Comparator
Placebo
Endpoint
3-point MACE
REWIND Trial
Tested
Dulaglutide 1.5mg weekly
Population
T2DM patients with CV risk factors
Comparator
Placebo
Endpoint
3-point MACE
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis